Precigen (PGEN) Competitors $1.56 +0.01 (+0.32%) As of 02:36 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PGEN vs. ARQT, IDYA, AGIO, CGON, ANIP, APGE, IMCR, KNSA, IRON, and SPRYShould you be buying Precigen stock or one of its competitors? The main competitors of Precigen include Arcutis Biotherapeutics (ARQT), IDEAYA Biosciences (IDYA), Agios Pharmaceuticals (AGIO), CG Oncology (CGON), ANI Pharmaceuticals (ANIP), Apogee Therapeutics (APGE), Immunocore (IMCR), Kiniksa Pharmaceuticals (KNSA), Disc Medicine (IRON), and ARS Pharmaceuticals (SPRY). These companies are all part of the "pharmaceutical products" industry. Precigen vs. Arcutis Biotherapeutics IDEAYA Biosciences Agios Pharmaceuticals CG Oncology ANI Pharmaceuticals Apogee Therapeutics Immunocore Kiniksa Pharmaceuticals Disc Medicine ARS Pharmaceuticals Arcutis Biotherapeutics (NASDAQ:ARQT) and Precigen (NASDAQ:PGEN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, community ranking, dividends, media sentiment, risk, valuation and institutional ownership. Do analysts recommend ARQT or PGEN? Arcutis Biotherapeutics presently has a consensus price target of $18.80, suggesting a potential upside of 29.43%. Precigen has a consensus price target of $7.00, suggesting a potential upside of 347.28%. Given Precigen's stronger consensus rating and higher possible upside, analysts clearly believe Precigen is more favorable than Arcutis Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcutis Biotherapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Precigen 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is ARQT or PGEN more profitable? Arcutis Biotherapeutics has a net margin of -140.97% compared to Precigen's net margin of -3,521.68%. Arcutis Biotherapeutics' return on equity of -119.11% beat Precigen's return on equity.Company Net Margins Return on Equity Return on Assets Arcutis Biotherapeutics-140.97% -119.11% -45.95% Precigen -3,521.68%-123.06%-87.33% Which has more risk and volatility, ARQT or PGEN? Arcutis Biotherapeutics has a beta of 1.67, suggesting that its share price is 67% more volatile than the S&P 500. Comparatively, Precigen has a beta of 1.7, suggesting that its share price is 70% more volatile than the S&P 500. Which has higher valuation and earnings, ARQT or PGEN? Precigen has lower revenue, but higher earnings than Arcutis Biotherapeutics. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArcutis Biotherapeutics$196.54M8.77-$262.14M-$1.16-12.52Precigen$3.93M117.24-$95.90M-$0.48-3.26 Does the media favor ARQT or PGEN? In the previous week, Arcutis Biotherapeutics had 4 more articles in the media than Precigen. MarketBeat recorded 5 mentions for Arcutis Biotherapeutics and 1 mentions for Precigen. Precigen's average media sentiment score of 1.72 beat Arcutis Biotherapeutics' score of 1.17 indicating that Precigen is being referred to more favorably in the news media. Company Overall Sentiment Arcutis Biotherapeutics Positive Precigen Very Positive Does the MarketBeat Community believe in ARQT or PGEN? Precigen received 365 more outperform votes than Arcutis Biotherapeutics when rated by MarketBeat users. However, 67.92% of users gave Arcutis Biotherapeutics an outperform vote while only 67.44% of users gave Precigen an outperform vote. CompanyUnderperformOutperformArcutis BiotherapeuticsOutperform Votes7267.92% Underperform Votes3432.08% PrecigenOutperform Votes43767.44% Underperform Votes21132.56% Do institutionals & insiders believe in ARQT or PGEN? 33.5% of Precigen shares are held by institutional investors. 9.5% of Arcutis Biotherapeutics shares are held by company insiders. Comparatively, 44.9% of Precigen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryPrecigen beats Arcutis Biotherapeutics on 11 of the 18 factors compared between the two stocks. Get Precigen News Delivered to You Automatically Sign up to receive the latest news and ratings for PGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PGEN vs. The Competition Export to ExcelMetricPrecigenPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$460.18M$6.74B$5.50B$7.96BDividend YieldN/A3.05%5.11%4.23%P/E Ratio-2.857.3822.6318.55Price / Sales117.24241.88397.30103.38Price / CashN/A65.8538.1834.62Price / Book3.266.476.704.25Net Income-$95.90M$143.68M$3.23B$248.27M7 Day Performance-1.57%1.85%1.36%1.28%1 Month Performance9.06%6.73%3.85%3.75%1 Year Performance11.79%-2.72%15.87%5.31% Precigen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PGENPrecigen3.6794 of 5 stars$1.57+0.3%$7.00+347.3%+18.2%$460.18M$3.93M-2.85190News CoveragePositive NewsARQTArcutis Biotherapeutics2.7566 of 5 stars$13.53+4.0%$18.80+39.0%+79.2%$1.61B$196.54M-7.56150Upcoming EarningsPositive NewsIDYAIDEAYA Biosciences3.7119 of 5 stars$18.18+6.4%$53.58+194.7%-50.5%$1.59B$7M-5.5180Upcoming EarningsPositive NewsAGIOAgios Pharmaceuticals4.2368 of 5 stars$27.34-1.2%$56.57+106.9%-8.6%$1.57B$36.50M2.41390Earnings ReportAnalyst RevisionNews CoverageCGONCG Oncology2.1113 of 5 stars$20.41-1.1%$59.33+190.7%-33.0%$1.56B$1.14M-14.3761Upcoming EarningsAnalyst ForecastNews CoverageANIPANI Pharmaceuticals4.4481 of 5 stars$68.00-1.7%$80.13+17.8%+7.3%$1.48B$614.38M-123.64600Positive NewsAPGEApogee Therapeutics2.226 of 5 stars$32.85-0.8%$92.17+180.6%-22.0%$1.48BN/A-13.5791News CoveragePositive NewsIMCRImmunocore3.1973 of 5 stars$29.41+3.5%$63.73+116.7%-49.1%$1.47B$310.20M-30.96320Upcoming EarningsNews CoveragePositive NewsKNSAKiniksa Pharmaceuticals2.4929 of 5 stars$20.05-0.8%$37.17+85.4%+44.1%$1.46B$423.24M-143.20220Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageIRONDisc Medicine2.3683 of 5 stars$42.06-0.3%$93.80+123.0%+77.5%$1.45BN/A-10.5730Upcoming EarningsNews CoveragePositive NewsSPRYARS Pharmaceuticals3.1313 of 5 stars$14.32-3.8%$31.00+116.5%+60.6%$1.41B$89.15M-28.0890Upcoming EarningsNews CoveragePositive NewsHigh Trading Volume Related Companies and Tools Related Companies ARQT Competitors IDYA Competitors AGIO Competitors CGON Competitors ANIP Competitors APGE Competitors IMCR Competitors KNSA Competitors IRON Competitors SPRY Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PGEN) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Precigen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Precigen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PGEN Stock Free PGEN Stock Alerts